In a recent study, olokizumab proved safe and effective for treating the signs and symptoms of RA and improving patients’ physical function…
Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer and editor. She is also a pharmacist at New York Presbyterian Hospital–Lower Manhattan campus. She has been a past guest lecturer at Touro College of Pharmacy in New York City for the Medical Writing elective. Dr Kaufman is a member of the New York City Society of Health-Systems Pharmacy, the New York State Council of Health-System Pharmacists, the Academy of Managed Care Pharmacy (AMCP)—Northeast Region Affiliate Chapter, the American Society of Consultant Pharmacists and the Empire State-Metropolitan NY Chapter of the American Medical Writers Association. She received her BS in Pharmacy from the University of Rhode Island (URI) College of Pharmacy and her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Allied Health Sciences in Boston. She also completed a Drug Information Fellowship at the URI Drug Information Center/Roger Williams Medical Center in Providence, R.I. Dr Kaufman is a registered pharmacist and is a Board-Certified Geriatric Pharmacist.
Articles by Michele B. Kaufman, PharmD, BCGP
FDA Advisory Committees Reject Oxycodegol (NKTR-181) Application
FDA advisory committees rejected the new drug application for oxycodegol, an opioid analgesic, due to a lack of data regarding it’s potential for abuse…
Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…
Canada & E.U. Approve Upadacitinib for RA
Upadacitinib will soon be available to treat patients with moderate to severe rheumatoid arthritis in Canada and the E.U…
New Gabapentinoid Warning Labels
Gabapentinoid products will now carry warning labels about the risks of respiratory distress when combined with opioids and other nervous system and respiratory depressants…
Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis
In a phase 3 study, ixekizumab proved safe and effective for improving the signs and symptoms of non-radiographic axial spondyloarthritis (axSpA) in combination with conventional background medications, such as NSAIDs…
EU Approves Remsima SC, a Biosimilar to Infliximab
Subcutaneous CT-P13 (Remsima SC), biosimilar to infliximab, will soon be available in the E.U. to treat adults with rheumatoid arthritis…
Anifrolumab Promising for SLE
Recent research has found a higher does of anifrolumab may benefit patients with moderate to severe SLE…
Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout
Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…
Tildrakizumab Promising for Psoriasis in Patients with PsA
New research shows tildrakizumab may significantly improve psoriasis in patients with active psoriatic arthritis…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 43
- Next Page »